I propose to take Questions Nos. 739 and 740 together.
The HSE operates the EU Treatment Abroad Scheme (TAS), for persons entitled under EU Regulation 883/04. The TAS is a consultant led scheme and allows for an Ireland-based public consultant to refer a public patient who is normally resident in Ireland for treatment in the public healthcare system of another EU member state, the UK or Switzerland. Subject to the EU Regulations and Guidelines, the TAS provides for the cost of approved public treatments in another EU/EEA member state, the UK or Switzerland through the issue of form S2 (IE) where the treatment is:
-among the benefits provided for by Irish legislation;
-not available in Ireland;
-not available within the time normally necessary for obtaining it in Ireland, taking account of the patient's current state of health and the probable course of the disease;
-medically necessary and will meet the patient’s needs;
-a proven form of medical treatment and not experimental or test treatment;
-provided in a recognised public hospital or other institution that will accept EU/EEA form S2 (IE) and;
-is under the control of a registered medical practitioner.
The HSE also operates the EU Cross Border Directive and the Northern Ireland Planned Healthcare Scheme that facilitates patients accessing treatment abroad. Patients are advised to contact the HSE for advice on making an application for treatment abroad under the most appropriate scheme, in advance of travelling abroad. Further information is available on the HSE's TAS, CBD / Northern Ireland Planned Healthcare Scheme websites, including contact details.
As this is a service matter, I have also asked the Health Service Executive to respond to the deputy directly, as soon as possible.